5. Management After Lung Transplant

Quick Recap

1. Definition

Lung transplantation is an accepted treatment for end-stage lung disease, but carries a 5-year survival of 50% or lower — lower than other solid organ transplants. Recent survival improvements have concentrated specifically in the early post-transplant period, likely reflecting better patient selection, surgical technique, and critical care rather than changes in long-term biology. Common indications: obstructive disease (COPD, obliterative bronchiolitis), interstitial/fibrotic disease (IPF, sarcoid, connective-tissue-disease-related ILD, LAM), suppurative disease (cystic fibrosis, non-CF bronchiectasis), and pulmonary vascular disease (primary pulmonary hypertension). Recipient selection generally requires single-organ failure and no uncontrolled active systemic infection at the time of transplant; combined heart-lung transplant is reserved for complex congenital heart disease, primary pulmonary hypertension, or the conditions above with concurrent poor cardiac function.

2. Primary Graft Dysfunction — The Central Early Complication

Primary graft dysfunction (PGD) is an ARDS-like clinical syndrome developing within the first 72 hours post-transplant — historically also called ischemia-reperfusion injury, noncardiogenic pulmonary edema, or reimplantation edema before the terminology was standardized in 2005. PGD is the most common early complication and a major driver of both early mortality and reduced long-term survival.

ISHLT Grading System (2016 update)

Graded 0-3 based on PaO2/FiO2 ratio and presence of radiographic infiltrates consistent with pulmonary edema, assessed at T0 (reperfusion of the second lung), then at 24, 48, and 72 hours:

Critical grading caveat: absence of infiltrates on chest radiograph is graded PGD 0 regardless of the P/F ratio — the radiographic finding, not hypoxemia alone, anchors grade 0. Measurement should ideally occur on PEEP 5cmH2O at FiO2 1.0; inhaled nitric oxide or other agents improving oxygenation should not change the grading method (i.e., don't grade based on oxygenation achieved after starting a pulmonary vasodilator). PGD is a diagnosis of exclusion — alternative causes of impaired gas exchange (discussed in Section 4) must be reasonably excluded first.

Why Grade 3 PGD Matters Beyond the Acute Period

PGD grade 3 specifically increases both recipient mortality and the risk of developing chronic lung allograft dysfunction (CLAD) later — the severe acute injury is a documented risk factor for long-term chronic rejection-type graft failure, not just an acute-phase concern. This is directly analogous to the heart transplant PGD-mortality link (Management After Heart Transplant, this section), reinforcing that primary graft dysfunction across both organ types is the dominant modifiable early risk factor shaping long-term outcome.

Emerging Prevention Strategy — Ex Vivo Lung Perfusion

Ex vivo lung perfusion (EVLP), used to recondition/assess marginal donor lungs before implantation, has shown a trend toward reduced PGD incidence in comparative data (15% vs. 30.1% in one study, though not reaching statistical significance in that particular comparison) — a genuinely promising but not yet definitively established donor-lung-optimization strategy.

3. Respiratory Management

• Extubation timing: generally 12-24 hours post-transplant if stable with good gas exchange and minimal pressure support — earlier extubation is associated with increased hypoxemia, hypercapnia, and respiratory distress, and prevents the bronchoscopic secretion clearance that may still be needed
• If oxygenation/ventilation proves difficult, actively consider: pulmonary edema, secretion accumulation, pneumothorax, pulmonary venous anastomotic occlusion/narrowing (can cause CXR shadowing, poor oxygenation, and pulmonary edema — TEE may be diagnostic), or reperfusion injury/PGD (may present 6-12 hours post-surgery)
• Pain control: epidural infusion is often most effective, particularly for clam-shell or thoracotomy incisions, and may allow earlier extubation — if not placed intraoperatively, it can be sited in the ICU before stopping sedation, provided clotting and full blood count have been checked first
• Chest drains: removed once there is no documented air leak and drainage is ≤100mL over 24 hours
• NIV/CPAP may be used post-extubation if oxygenation becomes suboptimal
• Surveillance bronchoscopy: used for secretion clearance and direct inspection of bronchial anastomoses; ischemic airway injury may be seen and is managed expectantly (not immediately treated as a complication requiring intervention); lung biopsy and BAL support histological rejection/infection assessment and microbiological diagnosis respectively

4. Cardiovascular Management

• PA catheter is recommended for regular pulmonary pressure and mixed venous saturation monitoring
• A falling mixed venous saturation can be an early indicator of poor perfusion or graft dysfunction — prompt further cardiac output studies to guide therapy rather than treating it as an isolated number
• Inotropic support is commonly required even with apparently normal preoperative cardiac function — low-dose dopamine alone may suffice in many cases
• Isoprenaline infusion is routinely used to maintain adequate heart rate and reduce pulmonary artery pressure
• Pulmonary hypertension control: nebulized prostacyclin is relatively easy to administer and effective

5. Immunosuppression

Induction

• Rabbit antithymocyte globulin most commonly used; IL-2 receptor-blocking antibodies (daclizumab, basiliximab) increasingly used as alternatives — a higher incidence of CMV infection may offset the lower acute rejection rates achieved with induction therapy, a genuine tradeoff rather than an unambiguous improvement
• High-dose IV prednisolone for the first 24 hours is standard

Maintenance

• Triple therapy (corticosteroid + azathioprine or mycophenolate + cyclosporine or tacrolimus), typically started 24 hours postoperatively
• Cyclosporine levels checked 2 hours post-dose to ensure adequate dosing and minimize renal impairment risk
• Tacrolimus can cause hyperglycemia but does not increase cholesterol; cannot be given through standard IV/NG giving sets — a practical administration detail worth knowing at the bedside
• mTOR inhibitors (everolimus, sirolimus): reasonable alternatives, but carry a real risk of wound dehiscence in the early postoperative period — should not be started before bronchial anastomotic healing is documented, which usually occurs by 6 weeks

6. Bleeding

Hemorrhage after lung transplant is more common when CPB is used intraoperatively. Other predisposing conditions: cystic fibrosis, bronchiectasis, sarcoidosis (all associated with dense pleural adhesions from chronic inflammatory lung disease, increasing surgical bleeding risk).

7. Consultation Matrix

8. Documentation & Medicolegal Checklist

• PGD grade documented at each ISHLT-specified timepoint (T0, 24h, 48h, 72h), with the specific P/F ratio and radiographic finding recorded
• Immunosuppression induction/maintenance regimen and any CMV surveillance plan documented
• Bronchial anastomotic healing confirmation documented before initiating an mTOR inhibitor

9. Key Guidelines

• 2016 ISHLT Working Group consensus statement on Primary Lung Graft Dysfunction (definition/grading, and epidemiology/risk factors/outcomes) remains the current standard grading framework

10. Landmark Evidence

11. Controversies

• PGD remains genuinely difficult to prevent despite two decades of standardized grading and study — this protocol treats it, consistent with the source literature's own framing, as "still a thorn in the side" of lung transplantation rather than a solved problem.
• The induction immunosuppression tradeoff (lower rejection vs. higher CMV infection) is a genuine, unresolved risk-benefit calculation rather than a clearly favorable choice in either direction — individualized based on rejection risk and CMV serostatus matching.
• EVLP's PGD-reduction signal is promising but not yet definitively established — the cited comparison did not reach statistical significance, meaning this remains an evolving rather than settled donor-optimization strategy.

12. References

1. Spencer L, Leonard C, Yonan N. Management after lung transplant. In: Klein AA, Vuylsteke A, Nashef SAM, eds. Core Topics in Cardiothoracic Critical Care. Cambridge: Cambridge University Press; 2008:412-417.
2. Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading—A 2016 Consensus Group statement. J Heart Lung Transplant. 2017;36(10):1097-1103.
3. Diamond JM, Arcasoy S, Kennedy CC, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes—2016 Consensus statement. J Heart Lung Transplant. 2017;36(10):1104-1113.
4. Wong KHM, Hsin KYM. Primary graft dysfunction in lung transplantation: still a thorn in the side of lung transplant. J Thorac Dis. 2024;16(1):1-5.
5. Management of primary graft dysfunction after lung transplantation with extracorporeal life support: an evidence-based review. J Thorac Dis. 2023.
6. Modified donor organs (EVLP outcomes data).

See also: Management After Heart Transplant (this section) for the parallel PGD-mortality link in cardiac transplantation; Postoperative Respiratory Failure (Surgical ICU System) for the general framework this protocol adds transplant-specific depth to; Post-Cardiotomy Mechanical Circulatory Support (this section) for ECMO/ECLS escalation in severe PGD.